Biogen (NASDAQ:BIIB) Issues Quarterly Earnings Results, Beats Expectations By $0.01 EPS

Biogen (NASDAQ:BIIB) issued its quarterly earnings data on Wednesday. The biotechnology company reported $3.44 EPS for the quarter, topping the consensus estimate of $3.43 by $0.01, Zacks reports. Biogen had a net margin of 16.81% and a return on equity of 14.98%. Biogen updated its FY 2025 guidance to 15.250-16.250 EPS.

Biogen Price Performance

Shares of Biogen stock traded down $6.81 during trading hours on Wednesday, reaching $132.58. 1,346,606 shares of the company’s stock were exchanged, compared to its average volume of 1,287,285. The business has a fifty day moving average of $148.28 and a two-hundred day moving average of $174.33. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The company has a market capitalization of $19.32 billion, a P/E ratio of 11.90, a price-to-earnings-growth ratio of 1.65 and a beta of -0.08. Biogen has a 1 year low of $128.51 and a 1 year high of $238.00.

Analyst Ratings Changes

Several brokerages have recently weighed in on BIIB. Sanford C. Bernstein initiated coverage on Biogen in a report on Tuesday. They set a “market perform” rating and a $160.00 price target for the company. Piper Sandler downgraded Biogen from an “overweight” rating to a “neutral” rating and dropped their price target for the stock from $315.00 to $138.00 in a research note on Thursday, January 2nd. Oppenheimer reduced their price objective on shares of Biogen from $270.00 to $255.00 and set an “outperform” rating on the stock in a research report on Thursday, October 31st. StockNews.com lowered shares of Biogen from a “strong-buy” rating to a “buy” rating in a research report on Saturday, December 28th. Finally, BMO Capital Markets cut shares of Biogen from an “outperform” rating to a “market perform” rating and decreased their price target for the stock from $230.00 to $164.00 in a research note on Friday, December 20th. Seventeen investment analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, Biogen currently has a consensus rating of “Hold” and an average target price of $221.65.

Biogen Company Profile

Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer’s disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.